Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07365826 · ClinicalTrials.gov registry record · Phase 3
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age
A Phase 3 study of Pneumococcal Vaccines, sponsored by Vaxcyte.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,300
- Enrollment target
- 20
- Study locations
NCT07365826 is a Phase 3 study of Pneumococcal Vaccines that is actively recruiting participants, run by Vaxcyte. The registered enrollment target is 1,300 participants, roughly in line with the 1,327-participant average among 5 other Pneumococcal Vaccines trials with a reported enrollment target. The trial reports 20 study locations across 13 states.
The verdict
NCT07365826, a Phase 3 study of Pneumococcal Vaccines, is actively recruiting participants, sponsored by Vaxcyte.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,300 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 3, randomized, double-blind study to evaluate the safety and immunogenicity of VAX-31 and seasonal influenza vaccine in pneumococcal-naïve adults ≥ 50 years when the two vaccines are administered at the same visit or separately.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL 31-valent pneumococcal conjugate vaccine
- BIOLOGICAL Seasonal Influenza Vaccine (SIV) (Flublok)
Study Locations (20)
Florida
- University Clinical Research - Deland - DeLand
- CenExel Research Centers of America - Hollywood
- Health Awareness - Jupiter
- Accel Research Sites - Lakeland - Lakeland
- Accel Research Sites - Largo - Largo
- Precision Clinical Research - Sunrise
Tennessee
- DelRicht Research - Hendersonville - Hendersonville
- AMR Knxoville - Knoxville
Texas
- Tekton Research at Austin - Austin
- REX Clinical Trials - Beaumont
Arizona
- Hope Research Institute - Phoenix
Colorado
- Tekton Research at Fort Collins - Fort Collins
Indiana
- Velocity Valparaiso - Valparaiso
Kansas
- Johnson County ClinTrials - Lenexa
Kentucky
- AMR Lexington - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,300 participants |
| Start Date | 2026-01-12 |
| Est. Completion | 2027-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07365826
The ClinicalTrials.gov registry entry for NCT07365826 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,300 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 1,327-participant average among 5 other Pneumococcal Vaccines trials with a reported enrollment target. The listed sponsor is Vaxcyte, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pneumococcal Vaccines appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT07365826 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, Tennessee, Texas.
Frequently Asked Questions
What is clinical trial NCT07365826 about?
NCT07365826 is a clinical study titled "A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age". This is a Phase 3, randomized, double-blind study to evaluate the safety and immunogenicity of VAX-31 and seasonal influenza vaccine in pneumococcal-naïve adults ≥ 50 years when the two vaccines are administered at the same visit or separately.
What is the current status of trial NCT07365826?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,300 participants. The study started on 2026-01-12. Estimated completion is 2027-03.
What conditions does trial NCT07365826 study?
This clinical trial studies the following conditions: Pneumococcal Vaccines.
What interventions are being tested in trial NCT07365826?
The interventions under investigation include: Placebo (BIOLOGICAL), 31-valent pneumococcal conjugate vaccine (BIOLOGICAL), Seasonal Influenza Vaccine (SIV) (Flublok) (BIOLOGICAL).
Who is sponsoring clinical trial NCT07365826?
This trial is sponsored by Vaxcyte, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07365826 being conducted?
This trial has 20 study locations across Arizona, Colorado, Florida, Indiana, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pneumococcal Vaccines
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49
RECRUITING · Phase 3
-
Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination
RECRUITING · Phase 3
-
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants
ACTIVE NOT RECRUITING · Phase 2
-
Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants
COMPLETED · Phase 2
-
Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.